Learn More
OBJECTIVE To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the Fc-inactivated anti-β amyloid (Aβ) monoclonal antibody (mAb) GSK933776 in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI). METHODS This was a two-part, single blind, placebo-controlled, first-time-in-human (FTIH) study of single (n =(More)
436 patients with various infections were treated with 2 kinds of enoxacin preparations, tablets in 336 cases and capsules in 100 cases. The total effective rate for tablets and capsules was 97.0% and 95.0% respectively. The bacterial eradication rate was 96.8% for tablets and 96.7% for capsules. Adverse reactions were few and mild. A randomized study of(More)
  • 1